Comments on ‘Call for a Follow-UP Study of Experiments on Long-Term Deprivation of Human Infants’ by Micha Razel

1989 ◽  
Vol 64 (2) ◽  
pp. 397-398
Author(s):  
Burton L. White

Razel's examination of the early work of McGraw and the Dennises puts a heavy requirement on studies of single subjects and on some possible interpretations for which, unfortunately, documentation is insufficient. Further, the Dennises placed more emphasis on the autotelic quality of motor mastery than Razel notes. Rather than looking for these persons whose behavior was studied long ago, direct study of motor mastery by systematic provision of enrichment conditions during early development is more likely to be instructive and a better use of scientific resources.

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii352-iii352
Author(s):  
Hung Tran ◽  
Robert Cooper

Abstract PURPOSE To describe decreased growth velocity with long term use of BRAFV600e and MEK inhibition in a patient with anaplastic ganglioglioma. RESULTS 4-year-old patient was found to have a 6 x 4.6 x 5 cm mass in the hypothalamus. Pathology consistent with anaplastic ganglioglioma and chromosomal microarray revealed a BRAFV600e mutation. Patient started on dabrafenib and trametinib and tumor decreased 85% after 3 months. She is stable without significant toxicities 39 months on therapy, and is now 8 years old. Patient had been growing at the 25% for weight and 12% for height but is now 65% for weight and 0.5% for height. It is difficult to tease out the relationship between the tumor, the location of the tumor, and the BRAF and MEK inhibitors and their effect on growth. Discussions with the family and endocrinology are ongoing but being <1% for height will lead to decrease in quality of life. CONCLUSIONS Further follow-up study is needed to determine if this is truly a long-term toxicity, or if this may just be a direct result of the location of the tumor. Would supplementation with growth hormone in this patient lead to losing control of a high grade tumor, or would it simply replace a hormone that is not produced?


Critical Care ◽  
2008 ◽  
Vol 12 (5) ◽  
pp. 429 ◽  
Author(s):  
Christopher J Longo ◽  
Daren K Heyland ◽  
Harold N Fisher ◽  
Robert A Fowler ◽  
Claudio M Martin ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
pp. 105-115 ◽  
Author(s):  
Christel Bruggmann ◽  
Juan F. Iglesias ◽  
Marianne Gex-Fabry ◽  
Rachel Fesselet ◽  
Pierre Vogt ◽  
...  

2006 ◽  
Vol 61 (6) ◽  
pp. 835-839 ◽  
Author(s):  
Renee R. Taylor ◽  
Sachi G. Thanawala ◽  
Yukiko Shiraishi ◽  
Michael E. Schoeny

2015 ◽  
Vol 25 (3) ◽  
pp. 687-697 ◽  
Author(s):  
Tarja H. Välimäki ◽  
Janne A. Martikainen ◽  
Kristiina Hongisto ◽  
Saku Väätäinen ◽  
Harri Sintonen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document